248,549 Orion Corporation A shares converted into B shares

   
  
ORION CORPORATION      STOCK EXCHANGE RELEASE 1 JUNE 2017 at 9.20 a.m. EEST              

248,549 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 248,549 A shares have been converted into 248,549 B shares. The conversion has been entered into the Trade Register on 1 June 2017.

The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 37,453,479 A shares and 103,804,349 B shares. The number of votes of the company’s shares is after the conversion 852,873,929.

  
Orion Corporation

Olli Huotari
SVP, Corporate Functions
  Jari Karlson
CFO
 

                                                                       

                                                                       
Contact person:
Terhi Ormio, Vice President, Communications, tel. +358 10 426 4646

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion’s A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.

Ads

You May Also Like

CrownBio推出新的人源化靶点模型以推进免疫疗法

圣地亚哥,加利福尼亚州, May 04, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience是Crown Bioscience International (TWSE:6554) 的全资子公司,是一家提供移植平台以促进肿瘤、炎症、心血管和代谢疾病的研发服务公司,CrownBio近期推出了一种新的转基因CD3E模型,丰富了原有的人源化药物靶点模型(HuGEMM™)产品系列,以促进免疫肿瘤学药物的研发。 新兴的T细胞重定向治疗抗体,包括双特异性T细胞,展示了有效治疗癌症的潜力。但是,这些药物的研发由于缺乏能准确再现人体药效反应的模型而受到限制。CrownBio与南京大学NBRI合作研发验证的新型CD3E转基因模型解决了药物研发对模型的需求。 ...